GLG News by Aranesp Prescribers (US)
Request a free trial
September 29, 2008
Oh, Good, Not only won't seniors be able to understand it; they won't be able to afford it?
Analysis of: Medicare Drug Premium on Rise | online.wsj.com
Author: GLG Expert Contributor
Analysis of: Medicare Drug Premium on Rise | online.wsj.com
Author: GLG Expert Contributor
Costs for Medicare part D are going up 31%
September 26, 2008
Molecular profiles in lung cancer: THE FUTURE IS HERE....
Analysis of: Lung Cancer | content.nejm.org
Author: GLG Expert Contributor
Analysis of: Lung Cancer | content.nejm.org
Author: GLG Expert Contributor
Clinical trials are being built around determining which molecular profiles require what therapy. It's here!!
September 24, 2008
Lilly to Disclose Payments to Doctors: What a revolting development this is!
Analysis of: Lilly to Disclose Payments to Doctors | online.wsj.com
Author: GLG Expert Contributor
Analysis of: Lilly to Disclose Payments to Doctors | online.wsj.com
Author: GLG Expert Contributor
It will become public knowledge what Doctors are paid by Lilly for advice, lectures and other services.
September 23, 2008
3 week radiation for breast cancer: What is the cosmetic end result?
Analysis of: Shorter Radiation for Cancer of the Breast | www.nytimes.com
Author: GLG Expert Contributor
Analysis of: Shorter Radiation for Cancer of the Breast | www.nytimes.com
Author: GLG Expert Contributor
Results are identicle (3 weeks v 5 in post lumpectomy radiation?)
September 22, 2008
Can physicians adapt to proposed IT requirements?
Analysis of: Stark Offers Bill to Hasten e-record Adoption | modernhealthcare.com
Author: GLG Expert Contributor
Analysis of: Stark Offers Bill to Hasten e-record Adoption | modernhealthcare.com
Author: GLG Expert Contributor
Adoption of mandatory computerization will be gently forced on physicians and their offices
September 19, 2008
I know, I know there is no money in diagnostics but....
Analysis of: Raising the Profile of Cancer of Unknown Primary | jco.ascopubs.org
Author: GLG Expert Contributor
Analysis of: Raising the Profile of Cancer of Unknown Primary | jco.ascopubs.org
Author: GLG Expert Contributor
RNA gene profiling will allow up to get a better handle on the primary site, especially with increasing targeting opportunities in many neoplasms.
September 18, 2008
"Star Wars" technology interfaces with radiation oncology
Analysis of: Proton Radiotherapy: A Review | www.nytimes.com
Author: GLG Expert Contributor
Analysis of: Proton Radiotherapy: A Review | www.nytimes.com
Author: GLG Expert Contributor
Proton beam therapy will effect the market place and force competition for oncology centers to get "the next best thing."
September 9, 2008
Velcade 1st line? No surprise.....
Analysis of: Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Analysis of: Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Velcade, given with Melphalan & Prednisone approved for use 1st line in non-transplant myeloma patients first line.
September 9, 2008
IT'S ALIVE!!?? Astra Zeneca's (AZ) Iressa (At least in Japan)
Analysis of: Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study | jco.ascopubs.org
Author: GLG Expert Contributor
Analysis of: Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study | jco.ascopubs.org
Author: GLG Expert Contributor
2 separate studies show that: 1. "...there was no statistically significant difference in overall survival....for gefitinib compared with docetaxel. Gefitinib remains an effective treatment option for previously treated Japanese patients with NSCLC." http://jco.ascopubs.org/cgi/content/full/26/26/4244...
September 8, 2008
Think about the future and what this will lead to....
Analysis of: In Long-Awaited Maps of Cancer, The Breakthrough Is the Problem | online.wsj.com
Author: GLG Expert Contributor
Analysis of: In Long-Awaited Maps of Cancer, The Breakthrough Is the Problem | online.wsj.com
Author: GLG Expert Contributor
Pharmacogenomics will lead to the development of targeting agents and offer true hope for the future.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 582
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

